Health Catalyst Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SALT LAKE CITY, July 29, 2019 /PRNewswire/ — Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the closing of its initial public offering of 8,050,000 shares of its common stock at a price to the public of $26.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,050,000 additional shares of common stock for total gross proceeds of $209.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Health Catalyst. Health Catalyst’s common stock began trading on The Nasdaq Global Select Market under the symbol “HCAT” on July 25, 2019.

Goldman Sachs & Co. LLC, J.P. Morgan, and William Blair acted as joint book-running managers for the offering as representatives of the underwriters. Piper Jaffray, Evercore ISI and SVB Leerink acted as passive book-running managers for the offering. SunTrust Robinson Humphrey acted as a co-manager for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; or from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, telephone: 1-800-621-0687.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations, committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records, and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Health Catalyst Investor Relations Contact:

Adam Brown
Senior Vice President, Investor Relations
+1 (855) 309-6800
ir@healthcatalyst.com

Health Catalyst Media Contact:

Kristen Berry
Vice President, Public Relations
+1 (617) 234-4123
+1 (774) 573-0455 (m)
kberry@we-worldwide.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/health-catalyst-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300892637.html

SOURCE Health Catalyst

Staff

Recent Posts

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

2 hours ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

2 hours ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

2 hours ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

2 hours ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year…

2 hours ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW)…

2 hours ago